AmMax Bio and MD Anderson Announce Agreements to Advance Development of AMB-066 in Colorectal Cancer Patients with Minimal Residual Disease
10. Dezember 2024 08:00 ET
|
AmMax Bio, Inc.
AmMax Bio and MD Anderson to Advance Development of AMB-066 in Colorectal Cancer Patients with Minimal Residual Disease
Myriad Genetics Announces Five Research Collaborations to Study the Use of MRD Testing in Breast Cancer
08. Oktober 2024 16:05 ET
|
Myriad Genetics, Inc.
SALT LAKE CITY, Oct. 08, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced a series of ongoing research...
Myriad Genetics and Ultima Genomics to Explore the UG 100™ Sequencing Platform to Advance Clinical Test Offerings in Oncology and Reproductive Genomics
03. Oktober 2024 09:00 ET
|
Myriad Genetics, Inc.
SALT LAKE CITY and FREMONT, Calif., Oct. 03, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, and Ultima Genomics, Inc., a...
Myriad Genetics Announces Third Patent Granted for Molecular Residual Disease (MRD) with Early Priority Date
01. Oktober 2024 16:05 ET
|
Myriad Genetics, Inc.
SALT LAKE CITY, Oct. 01, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced that the United States Patent and...
AmMax Bio to Present at the Oppenheimer Healthcare Private Company Showcase
27. September 2024 08:33 ET
|
AmMax Bio, Inc.
REDWOOD CITY, Calif., Sept. 27, 2024 (GLOBE NEWSWIRE) -- AmMax Bio, Inc., a private clinical-stage biopharmaceutical company developing innovative therapeutics in oncology, today announced that it...
Burning Rock Reports Second Quarter 2024 Financial Results
22. August 2024 23:59 ET
|
Burning Rock Biotech Limited
Burning Rock Reports Second Quarter 2024 Financial Results
Myriad Genetics and Personalis Cross-License Foundational MRD Intellectual Property to Broaden Patient Access to Testing
11. Juli 2024 09:00 ET
|
Myriad Genetics, Inc.
SALT LAKE CITY and FREMONT, Calif., July 11, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq: MYGN), a leader in genetic testing and precision medicine, and Personalis, Inc. (Nasdaq: PSNL)...
Burning Rock Reports First Quarter 2024 Financial Results
29. Mai 2024 01:34 ET
|
Burning Rock Biotech Limited
Burning Rock Reports First Quarter 2024 Financial Results
International Myeloma Foundation Celebrates ODAC Meeting Outcome on Minimal Residual Disease (MRD) Testing as an Early Endpoint for the Accelerated Approval of Myeloma Drugs in Clinical Trials: A Huge Win for the Global Myeloma Community
12. April 2024 16:08 ET
|
International Myeloma Foundation
International Myeloma Foundation Celebrates ODAC Meeting on Minimal Residual Disease (MRD) Testing as an Early Endpoint for the Accelerated Approval.
Burning Rock Reports Fourth Quarter and Full Year 2023 Financial Results
28. März 2024 17:16 ET
|
Burning Rock Biotech Limited
Burning Rock Reports Fourth Quarter and Full Year 2023 Financial Results